ALDEYRA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $29.8M | $16.3M | $13.2M | $7.6M | $3.7M | $1.5M |
| SG&A Expense | $9.9M | $6.2M | $5.5M | $4.4M | $3.6M | $2.1M |
| Operating Income | $-39.7M | $-22.5M | $-18.7M | $-12.0M | $-7.3M | $-3.7M |
| Operating Margin | — | — | — | — | — | — |
| Interest Expense | $146.8K | $113.5K | $105.5K | $112.3K | $244.2K | $159.3K |
| Pretax Income | $-38.9M | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | $-38.9M | $-22.3M | $-18.7M | $-12.1M | $-5.2M | $13.1M |
| Net Margin | — | — | — | — | — | — |
| EPS (Basic) | $-1.79 | $-1.40 | $-1.65 | $-1.40 | $-1.26 | $0.35 |
| EPS (Diluted) | $-1.79 | $-1.40 | $-1.65 | $-1.40 | $-1.55 | $-1.76 |
| Shares Outstanding (Basic) | 26.2M | 19.1M | 12.6M | 8.6M | 7.6M | 3.2M |
| Shares Outstanding (Diluted) | 26.2M | 19.1M | 12.6M | 8.6M | 7.7M | 8.6M |
| Dividends Per Share | — | — | — | — | — | — |